Figure 4From: CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery Symptomatic patients who underwent secondary CRS had shorter OS (A) and PFS (B) durations than asymptomatic patients. Back to article page